Mild Intermittent Hypoxia for Spinal Cord Injury
(MIH and AD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if mild intermittent hypoxia (controlled exposure to low oxygen levels) can alleviate autonomic dysfunction in individuals with spinal cord injuries. Autonomic dysfunction can cause issues like blood pressure problems, impacting daily activities and independence. Participants will receive either mild intermittent hypoxia or a sham treatment (normal air) in a lab setting. The trial seeks individuals with incomplete spinal cord injuries at or above the 12th thoracic vertebrae, who have had their injury for over a year and show signs of autonomic dysfunction, such as issues with heart rate and blood pressure. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could enhance daily life for those with spinal cord injuries.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that mild intermittent hypoxia is safe for individuals with spinal cord injury?
Research has shown that mild intermittent hypoxia (MIH), which involves breathing air with less oxygen for short periods, has been studied for safety. Some studies on animals and humans suggest it is generally safe, although it might cause oxidative stress, which is damage from free radicals in the body. While MIH can be safe, scientists must monitor for any stress on the body during studies.
In other research, such as studies with older patients who have stable angina (chest pain), MIH was safe and even helped reduce symptoms. These findings suggest that MIH might be well-tolerated by different groups, but it's important to continue monitoring for any possible effects on the heart and overall health.12345Why are researchers excited about this trial?
Researchers are excited about the use of mild intermittent hypoxia for spinal cord injury because it offers a novel approach that could stimulate nerve recovery. Unlike standard treatments that focus on rehabilitation and medications to manage symptoms, this technique involves brief exposures to low oxygen levels, which may enhance the body's natural repair mechanisms. By maintaining slightly elevated carbon dioxide levels, it might optimize oxygen delivery to tissues, potentially leading to improved motor function. This innovative method could provide a new avenue for enhancing recovery in patients with spinal cord injuries.
What evidence suggests that mild intermittent hypoxia is effective for autonomic dysfunction in spinal cord injury?
Research has shown that mild intermittent hypoxia (MIH), which participants in this trial may receive, can help with nerve-related issues in people with spinal cord injuries (SCI). One study found that MIH improved systolic autonomic dysreflexia by 46% and alleviated low blood pressure when standing by 160%. This suggests MIH might help manage common blood pressure problems in people with SCI. Additionally, MIH has reduced sleep breathing issues. These findings indicate that MIH could enhance daily life and independence for people with SCI.14567
Who Is on the Research Team?
Gino Panza, PhD
Principal Investigator
John D. Dingell VA Medical Center, Detroit, MI
Are You a Good Fit for This Trial?
This trial is for individuals aged 18-60 with motor incomplete spinal cord injuries above the 6th thoracic vertebrae and signs of autonomic dysfunction. It's not for those with complete SCI, injuries below T6, disrupted sleep patterns, pregnancy, smokers, drug addiction, age outside the specified range or active skin sores.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive mild intermittent hypoxia (MIH) or sham air treatment for 8 days over a 2-week period, with concurrent CPAP treatment if diagnosed with sleep apnea
Follow-up
Participants are monitored for sustained impact of therapeutic MIH on autonomic function and SDB, with assessments conducted 4 weeks post-treatment
What Are the Treatments Tested in This Trial?
Interventions
- Mild Intermittent Hypoxia
- Sham
Mild Intermittent Hypoxia is already approved in United States, European Union for the following indications:
- Obstructive Sleep Apnea (OSA)
- Cardiovascular dysfunction
- Exercise performance fatigue
- Obstructive Sleep Apnea (OSA)
- Cardiovascular conditions
- Respiratory conditions
Find a Clinic Near You
Who Is Running the Clinical Trial?
VA Office of Research and Development
Lead Sponsor
John D. Dingell VA Medical Center
Collaborator